Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2019	Dec. 31, 2018
CURRENT ASSETS:
Cash and cash equivalents	$ 11,092	$ 13,116
Accounts receivable, net of allowance for doubtful accounts of $2,730 and $2,650 at 2019 and 2018, respectively	131,579	129,157
Inventories	50,163	45,664
Prepaid expenses	15,951	15,351
Income taxes receivable	6,527	13,993
Other current assets	5,925	13,696
TOTAL CURRENT ASSETS	221,237	230,977
PROPERTY, PLANT AND EQUIPMENT, net	123,506	122,917
RIGHT OF USE ASSETS	75,697
INTANGIBLES, net	17,450	13,054
GOODWILL	213,425	219,412
DEFERRED TAX ASSETS, net	67,312	11,252
OTHER ASSETS	56,046	51,215
TOTAL ASSETS	774,673	648,827
CURRENT LIABILITIES:
Accounts payable	35,611	41,155
Accrued payroll and related costs	26,689	22,549
Taxes other than payroll and income	8,366	7,488
Unearned revenues	13,381	17,325
Operating lease liabilities	11,841
Income taxes payable	6,324	2,917
Other current liabilities	9,382	11,113
TOTAL CURRENT LIABILITIES	111,594	102,547
LONG-TERM DEBT, net	305,283	289,770
LONG-TERM OPERATING LEASE LIABILITIES	64,660
DEFERRED COMPENSATION	50,485	49,359
DEFERRED TAX LIABILITIES, net	27,338	7,634
OTHER LONG-TERM LIABILITIES	33,173	38,617
COMMITMENTS AND CONTINGENCIES
EQUITY:
Preference shares, EUR 0.02 par value; 6,000,000 shares authorized, none issued or outstanding
Common shares, EUR 0.02 par value; 200,000,000 shares authorized, 44,796,252 issued and 44,465,562 outstanding at 2019 and 44,796,252 issued and 44,316,845 outstanding at 2018	1,148	1,148
Additional paid-in capital	51,872	57,438
Retained earnings	160,539	156,130
Accumulated other comprehensive income (loss)	(6,330)	(5,456)
Treasury shares (at cost), 330,690 at 2019 and 479,407 at 2018	(29,364)	(52,501)
Total Core Laboratories N.V. shareholders' equity	177,865	156,759
Non-controlling interest	4,275	4,141
TOTAL EQUITY	182,140	160,900
TOTAL LIABILITIES AND EQUITY	$ 774,673	$ 648,827